Biogen's Aduhelm can't catch a break even in Alzheimer's trials as neurologists worry about safety,

[anonymous]

Biogen's Aduhelm can't catch a break even in Alzheimer's trials as neurologists worry about safety, efficacy

https://www.fiercepharma.com/market...als-cms-decision-has-not-killed-hope-all-anti

 

[anonymous]

“None of my patients are willing to take the risk [with Aduhelm]: 40% chance of ARIA-E or ARIA-H,” said one neurologist, quoted in the report. “And when I tell people there was minimal, if any, benefit and it is only for early Alzheimer’s, they’re like ‘Yeah, no thanks, we’re not interested.’”